Welcome to BC PharmaCare's public survey of drugs being reviewed for coverage. This survey is for tofacitinib (Xeljanz and generics ) for the treatment of adult patients with active psoriatic arthritis (PsA) with a previous inadequate response to a disease-modifying antirheumatic drug (DMARD).